Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Impact of Clinicopathological Factors on Outcomes of Uterine cancer in Zagazig University Hospitals: Retrospective Analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Abstract:
      المقال يركز على تأثير العوامل السريرية والمرضية على نتائج مرضى سرطان الرحم الذين تم علاجهم في مستشفيات جامعة الزقازيق في مصر. أظهرت تحليل رجعي لـ 152 مريضًا من يناير 2017 إلى ديسمبر 2022 أن المرحلة المتقدمة، والهيستولوجيا عالية الدرجة، وغزو الأوعية اللمفاوية، والغزو العميق لعضلة الرحم هي مؤشرات هامة للتنبؤ بسوء التشخيص. وجدت الدراسة أن العلاج الإشعاعي المساعد، وخاصة عند دمجه مع العلاج الكيميائي أو العلاج الإشعاعي الداخلي، قد حسّن بشكل كبير من معدلات البقاء على قيد الحياة. بينما كانت انقطاعات العلاج تؤثر سلبًا على النتائج. تؤكد النتائج على أهمية استراتيجيات العلاج المتعددة الأوجه وفي الوقت المناسب في تحسين بقاء المرضى. [Extracted from the article]
    • Abstract:
      Background: Uterine cancer is the most common gynecological malignancy in high and middle-income countries. We evaluated clinicopathologic features, treatments, and survival to identify prognostic factors in a real-world cohort. This research aimed to evaluate the clinicopathological characteristics, treatment modalities, and survival outcomes of uterine cancer patients at Zagazig University Hospitals. Methods: Retrospective review of 152 consecutive patients treated at Zagazig University Hospitals (January 2017-December 2022). Data on demographics, pathology, treatment, toxicity, and outcomes were abstracted from records. Endpoints were overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS). Results: Postmenopausal bleeding was the commonest symptom (67.8%). Management included combined local+systemic therapy (49.3%); surgery+radiotherapy (RT) in 67.1%; chemotherapy in 53.9%. Among 82 chemotherapy recipients, paclitaxel/carboplatin was used in 85.4%; treatment interruption occurred in 54%. RT was delivered to 107 patients (70% adjuvant); EBRT in 86%; interruptions >1 week in 25.2%. Overall, 36.2% recurred. Recurrence associated strongly with advanced FIGO stage and LVI (each p<0.001), and with Type II histology (p=0.012), cervical stromal invasion (p=0.03), and higher grade (p=0.01). Median PFS was 18 months (p=0.856); DFS 56 months (5-year 41.4%, p=0.058); OS 72 months (5-year 62.3%, p=0.003). On regression, adverse factors included, diabetes (p=0.048), ECOG 3 (p<0.001), high grade (p=0.043), LVI (p=0.031), deep invasion (p<0.001), and FIGO III-IV (p=0.014). Favorable factors were adjuvant RT (p<0.001), concurrent chemoradiotherapy (p=0.040), and combined local+systemic therapy (p=0.012). Toxicities were common but mainly grade 1-2. Conclusion: This study highlights that advanced stage, high-grade histology, lymphovascular invasion, and deep myometrial invasion are key predictors of poor prognosis in uterine cancer. Adjuvant radiotherapy, especially when combined with chemotherapy or brachytherapy, significantly improved survival. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Zagazig University Medical Journal is the property of Association of Arab Universities and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)